Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders

Addiction

Volumn 113, Issue 4, 2018, Pages 656-667

  Russolillo, Angela ^a   Moniruzzaman, Akm ^a   McCandless, Lawrence C ^a   Patterson, Michelle ^a   Somers, Julian M ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Crime; methadone; methadone maintenance treatment; MMT; offenders; substitution treatment

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; CANADA; COHORT ANALYSIS; CRIME; FEMALE; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PROPORTIONAL HAZARDS MODEL; VIOLENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CANADA; COHORT STUDIES; CRIME; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROPORTIONAL HAZARDS MODELS; VIOLENCE; YOUNG ADULT;

EID: 85034236749     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14059     Document Type: Article

References (54)

1. Degenhardt L., Whiteford H. A., Ferrari A. J., Baxter A. J., Charlson F. J., Hall P. W. D., et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1564–1574.
2. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55–70.
3. Fazel S., Baillargeon J. The health of prisoners. Lancet 2011; 377: 956–965.
4. Degenhardt L., Gisev N., Trevena J., Larney S., Kimber J., Burns L., et al. Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. Br J Addict 2013; 108: 2152–2165.
5. Gottfredson D., Kearley B., Bushway S. Substance use, drug treatment, and crime: an examination of intra-individual variation in a drug court population. J Drug Issues 2008; 38: 601–630.
6. Marel C., Mills K. L., Darke S., Ross J., Slade T., Burns L., et al. Static and dynamic predictors of criminal involvement among people with heroin dependence: findings from a 3-year longitudinal study. Drug Alcohol Depend 2013; 133: 600–606.
7. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; Issue 3. Art. No.: CD002209. https://doi.org/10.1002/14651858.CD002209.pub2.
8. Dole V. P., Robinson J. W., Orraca J., Towns E., Searcy P., Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969; 280: 1372–1375.
9. Mattick R. P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; Issue 2. Art. No.: CD002207. https://doi.org/10.1002/14651858.CD002207.pub4.
10. Hser Y.-I., Saxon A. J., Huang D., Hasson A., Thomas C., Hillhouse M. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2013; 109: 79–87.
11. Marsch L. A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93: 515–532.
12. Holloway K. R., Bennett T. H., Farrington D. P. The effectiveness of drug treatment programs in reducing criminal behavior: a meta-analysis. Psicothema 2006; 18: 620–629.
13. Zhang Z., Friedmann P. D., Gerstein D. R. Does retention matter? Treatment duration and improvement in drug use. Addiction 2003; 98: 673–684.
14. Dowden C., Brown S. L. The role of substance abuse factors in predicting recidivism: a meta-analysis. Psychol Crime Law 2002; 8: 243–264.
15. Burns L., Gisev N., Larney S., Dobbins T., Gibson A., Kimber J. et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015; 110: 646–655.
16. Bennett T., Holloway K., Farrington D. The statistical association between drug misuse and crime: a meta-analysis. Aggress Violent Behav 2008; 13: 107–118.
17. Lind B., Chen S., Weatherburn D., Mattick R. The effectiveness of methadone maintenance treatment in controlling crime: an Australian aggregate-level analysis. Br J Criminol 2004; 45: 201–211.
18. Dolan K. A., Shearer J., White B., Zhou J., Kaldor J., Wodak A. D. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005; 100: 820–828.
19. Gordon M. S., Kinlock T. W., Schwartz R. P., O'Grady K. E. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 2008; 103: 1333–1342.
20. Oliver P., Keen J., Rowse G., Ewins E., Griffiths L., Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction 2010; 105: 732–739.
21. Carrieri P., Vilotitch A., Nordmann S., Lions C., Michel L., Mora M., et al. Decrease in self-reported offences and incarceration rates during methadone treatment: a comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). Int J Drug Policy 2017; 39: 86–91.
22. Davstad I., Stenbacka M., Leifman A., Romelsjö A. An 18-year follow-up of patients admitted to methadone treatment for the first time. J Addict Dis 2009; 28: 39–52.
23. Larney S., Toson B., Burns L., Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction 2011; 107: 372–380.
24. Gossop M., Trakada K., Stewart D., Witton J. Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug Alcohol Depend 2005; 79: 295–302.
25. Havnes I., Bukten A., Gossop M., Waal H., Stangeland P., Clausen T. Reductions in convictions for violent crime during opioid maintenance treatment: a longitudinal national cohort study. Drug Alcohol Depend 2012; 124: 307–310.
26. Kinlock T. W., Gordon M. S., Schwartz R. P., Fitzgerald T. T., O'Grady K. E. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat 2009; 37: 277–285.
27. Kinlock T. W., Gordon M. S., Schwartz R. P., O'Grady K. E. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav 2008; 35: 34–47.
28. Macswain M. A., Farrell-MacDonald S., Cheverie M., Fischer B. Assessing the impact of methadone maintenance treatment (MMT) on post-release recidivism among male federal correctional inmates in Canada. Crim Justice Behav 2014; 41: 380–394.
29. Magura S., Lee J. D., Hershberger J., Joseph H., Marsch L., Shropshire C. et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend 2009; 99: 222–230.
30. Sun H.-M., Li X.-Y., Chow E., Li T., Xian Y., Lu Y.-H. et al. Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. BMJ Open 2015; 5: e005997.
31. Rezansoff S. N., Moniruzzaman A., Gress C., Somers J. M. Psychiatric diagnoses and multiyear criminal recidivism in a Canadian provincial offender population. Psychol Public Policy Law 2013; 19: 443–453.
32. Somers J. M., Moniruzzaman A., Rezansoff S. N., Brink J., Russolillo A. The prevalence and geographic distribution of complex co-occurring disorders: a population study. Epidemiol Psychiatr Sci 2015; 25: 267–277.
33. Somers J. M., Rezansoff S. N., Moniruzzaman A., Zabarauckas C. High-frequency use of corrections, health, and social services, and association with mental illness and substance use. Emerg Themes Epidemiol 2015; 12: 17.
34. Methadone and buprenorphine: Clinical practice guideline for opioid use disorder [internet]. College of Physicians and Surgeons of British Columbia. College of Physicians and Surgeons of British Columbia; 2016. pp. 1–68. Available at: https://www.cpsbc.ca/programs/drug-programs/mmp/methadone-opioid-use-disorder (accessed 3 November 2016) (Archived at http://www.webcitation.org/6uz9QXtiw).
35. Andersen P. K., Gill R. D. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100–1120.
36. Cox D. Regression models and life-tables. J R Stat Soc Series B (Methodological) 1972; 34: 187–220.
37. Grambsch P. M., Therneau T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526.
38. Hess K. R. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995; 14: 1707–1723.
39. Kalbfleisch J. D., Prentice R. L. The Statistical Analysis of Failure Time Data, 2nd edn. Hoboken, NJ: John Wiley & Sons; 2002.
40. Chang Z., Lichtenstein P., Långström N., Larsson H., Fazel S. Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA 2016; 316: 1798–1807.
41. Røislien J., Clausen T., Gran J. M., Bukten A. Accounting for individual differences and timing of events: estimating the effect of treatment on criminal convictions in heroin users. BMC Med Res Methodol 2014; 14: 68.
42. Huber P. J. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkely Symposium on Mathematical Statistics and Probability. Berkley, CA: University of California Press; 1967.
43. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817–838.
44. Vogel M., Dürsteler K. M., Walter M., Herdener M., Nordt C. Rethinking retention in treatment of opioid dependence—the eye of the beholder. Int J Drug Policy 2017; 39: 109–113.
45. Kritz S., Chu M., John-Hull C., Madray C., Louie B., Brown L. S. Opioid dependence as a chronic disease: the interrelationships between length of stay, methadone dose, and age on treatment outcome at an urban opioid treatment program. J Addict Dis 2009; 28: 53–56.
46. Krebs E., Kerr T., Montaner J., Wood E., Nosyk B. Dynamics in the costs of criminality among opioid dependent individuals. Drug Alcohol Depend 2014; 144: 193–200.
47. Csete J., Kamarulzaman A., Kazatchkine M., Altice F., Balicki M., Buxton J. et al. Public health and international drug policy. Lancet 2016; 387: 1427–1480.
48. DeKeseredy W. S. Canadian crime control in the new millennium: the influence of neo-conservative US policies and practices. Police Pract Res 2009; 10: 305–316.
49. Drucker E. Drug law, mass incarceration, and public health. Oregon Law Rev 2013; 91: 1097–1128.
50. Gordon T. Neoliberalism, racism, and the war on drugs in Canada. Soc Justice 2006; 33: 59–78.
51. Bellin E., Wesson J., Tomasino V., Nolan J., Glick A. J., Oquendo S. High dose methadone reduces criminal recidivism in opiate addicts. Addict Res 2009; 7: 19–29.
52. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; Issue 3. Art. No.: CD002208. https://doi.org/10.1002/14651858.CD002208.
53. Hedrich D., Alves P., Farrell M., Stöver H., Møller L., Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2011; 107: 501–517.
54. Stallwitz A., Stöver H. The impact of substitution treatment in prisons—a literature review. Int J Drug Policy 2007; 18: 464–474.